fashion -WSS

fashion

author：explore 2025-10-01 23:03:20 - browse：389

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

entertainment

WSS

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Adam's Take: Intra

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Chinese researcher claims birth of first gene

Trump Organization, Michael Cohen agree to settle million

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

fashion

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Cancer, immunology, HIV research ensnared in fetal tissue politics

As demand for Covid shots wanes, Moderna seeks its next success

Pfizer, Moderna say biotech, pharma drug development is a sprint

After affirmative action ruling, medical educators look to 'holistic review'

A new deal aims to ramp up use of AI in rehab care decisions

After affirmative action ruling, medical educators look to 'holistic review'

Asbestos ban is immediate, but health effects will linger for decades

23andMe had bad news about my health. I wish a person had delivered it

Surgeons perform first xenotransplant using CRISPR'd pig kidney

hotspot

Pfizer's RSV vaccine recommended for approval in Europe

Hey, doctors: Don't be no

Chinese researcher claims birth of first gene

EMA weighs against approval for Mirati's lung cancer drug

'Patient friction coefficient' can gauge a clinical trial's patient burden

Prosecutors say FTX founder Sam Bankman

leisure time

entertainment

hotspot

explore